103 related articles for article (PubMed ID: 20662847)
21. Polyclonal orbital and systemic infiltrates.
Rootman J; Patel S; Jewell L
Ophthalmology; 1984 Sep; 91(9):1112-7. PubMed ID: 6493720
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype.
Portell CA; Aronow ME; Rybicki LA; Macklis R; Singh AD; Sweetenham JW
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):203-10. PubMed ID: 24417911
[TBL] [Abstract][Full Text] [Related]
23. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
Shome D; Esmaeli B
Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
[TBL] [Abstract][Full Text] [Related]
24. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma.
Sagiv O; Thakar SD; Morrell G; Tetzlaff MT; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2018; 34(1):e24-e27. PubMed ID: 28863117
[TBL] [Abstract][Full Text] [Related]
25. Immunohistologic diagnosis of orbital lymphoid infiltrates.
Harris NL; Pilch BZ; Bhan AK; Harmon DC; Goodman ML
Am J Surg Pathol; 1984 Feb; 8(2):83-91. PubMed ID: 6367504
[TBL] [Abstract][Full Text] [Related]
26. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
[TBL] [Abstract][Full Text] [Related]
27. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
28. Idiopathic orbital inflammation successfully treated using rituximab in a patient with rheumatoid arthritis.
Ibrahim I; Barton A; Ibrahim A; Ho P
J Rheumatol; 2012 Jul; 39(7):1485-6. PubMed ID: 22753803
[No Abstract] [Full Text] [Related]
29. Rituximab therapy for refractory idiopathic scleritis.
Bogdanic-Werner K; Fernandez-Sanz G; Alejandre Alba N; Ferrer Soldevila P; Romero-Bueno FI; Sanchez-Pernaute O
Ocul Immunol Inflamm; 2013 Aug; 21(4):329-32. PubMed ID: 23662782
[TBL] [Abstract][Full Text] [Related]
30. Posttransplant lymphoproliferative disorder in an 11-year-old immunosuppressed boy.
Nelson A; Dhamija R; Nickels K
Pediatr Neurol; 2013 May; 48(5):397-9. PubMed ID: 23583059
[TBL] [Abstract][Full Text] [Related]
31. [Lymphoproliferative diseases of the orbit and appendages of the eye].
Nechesniuk SIu; Probatova NA; Grishina EE; Kovrigina AM; Tupitsyn NN; Sholokhova EN
Arkh Patol; 2001; 63(1):27-32. PubMed ID: 11242851
[TBL] [Abstract][Full Text] [Related]
32. Primary Central Nervous System Immunomodulatory Therapy-Induced Lymphoproliferative Disorder in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature.
Alobaid A; Torlakovic E; Kongkham P
World Neurosurg; 2015 Dec; 84(6):2074.e15-9. PubMed ID: 26171889
[TBL] [Abstract][Full Text] [Related]
33. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment with rituximab of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
Jericho H; Weinstein J; Melin-Aldana H; Leuer KC; Wyers M; Alonso EM; Ekong UD
J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):e2-4. PubMed ID: 24378523
[No Abstract] [Full Text] [Related]
35. [Efficacy of rituximab in refractory Wegener's granulomatosis with central nervous system involvement].
Kowalewska B; Krywejko J; Roszkowska E
Ann Acad Med Stetin; 2010; 56 Suppl 1():99-104. PubMed ID: 21365953
[TBL] [Abstract][Full Text] [Related]
36. Atypical lymphoid proliferation of the orbit.
Tan LTO; Trio-Ranche FKC
GMS Ophthalmol Cases; 2022; 12():Doc06. PubMed ID: 35291585
[No Abstract] [Full Text] [Related]
37. Treatment of a patient with adnexal lymphoma with Rituximab.
Bilgir O; Bilgir F; Calan M; Yuksel A; Sari F; Oztekin O
Transfus Apher Sci; 2011 Apr; 44(2):135-7. PubMed ID: 21320802
[TBL] [Abstract][Full Text] [Related]
38. An atypical presentation of persistent polyclonal B-lymphocytosis with symptomatic splenomegaly and response to rituximab.
Blombery P; Came N; Maxwell E; Herbert K
Pathology; 2013 Jun; 45(4):437-40. PubMed ID: 23635822
[No Abstract] [Full Text] [Related]
39. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
Musto P; D'Auria F
Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
[TBL] [Abstract][Full Text] [Related]
40. Resolution of lymphoma-associated open-angle glaucoma by rituximab.
Kim WI; Larar JG; Cheson BD; Lee RK; Palmberg PF
J Glaucoma; 2011 Aug; 20(6):398-400. PubMed ID: 20852443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
